NCT06326645View on ClinicalTrials.gov

Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

March 3, 2025

Primary Completion Date

February 1, 2026

Study Completion Date

February 1, 2026

Conditions
Short Bowel Syndrome
Interventions
DRUG

Crofelemer Oral Product

Crofelemer powder for solution (50g and 100g) or Crofelemer Powder for Oral Solution (100 mg/mL or 30 mg/mL vials for reconstitution and oral dosing)

Trial Locations (1)

44106

RECRUITING

Cleveland Clinic Main Campus, Cleveland

Sponsors
All Listed Sponsors
collaborator

Napo Pharmaceuticals, Inc.

INDUSTRY

lead

Lindsey Russell, MD

OTHER

NCT06326645 - Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome | Biotech Hunter | Biotech Hunter